Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy
Condition(s) studied
Study summary
The goal of this randomized controlled trial is to evaluate the safety, feasibility, and efficacy of psilocybin assisted therapy as an intervention to reduce symptom burden in adult patients (aged 18-65) with persisting symptoms after concussion (PSaC).
This trail will test the following 2 aims:
AIM 1 : To test the safety and feasibility of an active psilocybin-assisted psychotherapy to an active control for patients with PSaC.
AIM 2: To evaluate the efficacy of an active psilocybin-assisted psychotherapy compared to an active control as a treatment for PSaC.
Participants will be asked to:
* Complete a 2-part screening process
* Attend a baseline assessment
* Complete a psychoeducation preparation session(s)
* Attend psilocybin administration session (receive high dose \[25mg\] or low dose psilocybin \[1mg\])
* Complete 5 weekly sessions of Acceptance and commitment therapy (ACT)
* Repeat outcome measures at 1-week, 4 weeks, 3 months, and 6 months post-psilocybin administration (online only at 6 months).
Eligibility
Primary outcome measure(s)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — Throughout study completion, an average of 6 months
Safety will be determined based on adverse reactions and symptom reporting (categorized as mild, moderate, and severe) - Study protocol efficacy — Throughout study completion, an average of 6 months
The primary efficacy outcome is the Rivermead Post-Concussion Symptoms Questionnaire (RPQ).The RPQ assesses the severity of 16 commonly experienced PSaC symptoms using a scale of 0 ("not experienced") to 4 ("severe problem"), with higher scores indicating greater PSaC symptom burden. - Study protocol feasibility — Screening, enrolment, intervention, and participation up to study end point (6-months)
The feasibility will be determined based on recruitment (greater than 30% of those screened eligible), attendance (70% intervention appointment attendance), retention (70% complete study protocol)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Calgary | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06615908 on ClinicalTrials.gov ↗ ← All trials in Canada